



iPAAC
INNOVATIVE PARTNERSHIP
FOR ACTION AGAINST CANCER

HPV vaccination in the Czech Republic

Annex No. 1: Availability of HPV vaccination in the Czech Republic and in international comparison



Co-funded by
the Health Programme
of the European Union

HPV vaccination in EU member states (report from 2015)

Country	Type of programme	Age at vaccination	Vaccination coverage of the population in a given year (C: birth cohort)
Austria	Opportunistic	>9 (before sexual debut)	–
Belgium	Opportunistic/Organised (schools)	12–13	Opportunistic (2009) C1995: 37% School-based (2011) C1998: 83%
Bulgaria	Organised (healthcare facilities, GPs)	12	–
Denmark	Organised (GPs)	12	(2009) C1996: 79%
Finland	Organised (schools)	11–12	–
France	Opportunistic	11–14	(2008) C1994: 29%
Germany	Opportunistic	12–17	–
Greece	Opportunistic/Organised	12–15	–
Ireland	Organised (schools)	12–13	–
Iceland	Organised (schools)	12	–
Italy	Organised (healthcare facilities)	11	(2011) C1997: 66%
Latvia	Organised (healthcare facilities)	12	(2012) 53%
Luxembourg	Opportunistic	12–13	(2009) 17%
Malta	Organised (healthcare facilities)	12	(2013) 88%
the Netherlands	Organised (healthcare facilities)	12	(2012) C1997: 56%
Norway	Organised (schools)	12	(2011) C1997: 63%
Portugal	Organised (healthcare facilities)	13	(2009) 81%
Romania	Organised (schools)	12	–
Slovenia	Organised (schools)	11–12	(2011) 55%
United Kingdom	Organised (schools)	12–13	80%
Spain	Organised (healthcare facilities/schools)	11–14 (according to region)	(2009) 77%
Sweden	Organised (schools)	10–12	(2013) C2000–C2001: 82%

Source: European Guidelines for Quality Assurance in Cervical Cancer Screening (Second Edition Supplements)



EU member states without an HPV vaccination programme (report from 2015)

Country	Type of programme	Age at vaccination	Vaccination coverage of the population in a given year (C: birth cohort)
Croatia	-	-	-
Cyprus	-	-	-
Estonia	-	-	-
Hungary	-	-	-
Lithuania	-	-	-
Poland	-	-	-
Slovakia	-	-	-

Source: European Guidelines for Quality Assurance in Cervical Cancer Screening (Second Edition Supplements)

Overview of vaccines against HPV that are available in the Czech Republic (J07BM)

ATC code*	Description	Brand name	Maximum ex-factory price	Maximum reimbursement from health insurance	Rough price for the final consumer	Rough payment for the final consumer	Note
J07BM01	papillomavirus vaccines (human types 6, 11, 16, 18)	SILGARD	2,554 CZK	1,766 CZK	3,377 CZK	1,611 CZK	Termination of marketing of this medicinal product was reported on 15 July 2018.
J07BM01	papillomavirus vaccines (human types 6, 11, 16, 18)	GARDASIL	2,368 CZK	1,766 CZK	3,139 CZK	1,373 CZK	Irregular supply. The supply will probably be terminated and Gardasil 9 will be used instead.
J07BM02	papillomavirus vaccines (human types 16, 18)	CERVARIX	1,392 CZK	1,766 CZK	1,766 CZK	0 CZK	No payment is required from the final consumer.
J07BM03	papillomavirus vaccines (human types 6, 11, 16, 18, 31, 33, 45, 52, 58)	GARDASIL 9	3,077 CZK	1,766 CZK	4,033 CZK	2 267 CZK	

* The medicinal product is only reimbursed from the public health insurance if the first dose is administered between ages 13 and 14. Both girls and boys can be vaccinated under this scheme.

As for girls, HPV vaccination has been reimbursed since the 1 April 2012. The vaccination programme was extended in August 2017 to cover boys as well (by Draft Amendment to Act No. 290/2017 Coll.). The above-mentioned age interval applies to both sexes, effective from 1 January 2018.